Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Personalized Therapeutic Neuromodulation for Anhedonic Depression
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Active TBS-DLPFC
- device: Active TBS-DMPFC
- device: Sham TBS-DLPFC or DMPFC
Eligibility
Inclusion Criteria:
1. Male or Female, between the ages of 18 and 80 at the time of screening.
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Proficiency in English sufficient to complete questionnaires / follow
instructions during fMRI assessments and aiTBS interventions. Stated willingness to
comply with all study procedures, including availability for the duration of the
study, and to communicate with study personnel about adverse events and other
clinically important information.
3. Currently diagnosed with Major Depressive Disorder (MDD) or Bipolar Disorder type II
and meets criteria for a Major Depressive Episode, according to the criteria defined
in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text
Revision (DSM-5).
4. Medical records confirming a history of moderate to severe treatment-resistance as
defined by a score of 7-14 on the Maudsley Staging Method (MSM).
5. MADRS score of ≥20 at screening (Visit 1).
6. TMS naive.
7. Access to ongoing psychiatric care before and after completion of the study.
8. Must be on a stable antidepressant therapeutic regimen for 6 weeks prior to study
enrollment and agree to continue this regimen throughout the study period.
9. In good general health, as evidenced by medical history.
10. For females of reproductive potential: use of highly effective contraception for at
least 1 month prior to screening and agreement to use such a method during study
participation.
Exclusion Criteria:
1. Pregnancy
2. Primary psychiatric condition other than MDD requiring treatment except stable
co-morbid anxiety disorder
3. History of or current psychotic disorder or bipolar disorder
4. Diagnosis of Intellectual Disability or Autism Spectrum Disorder
5. Current moderate or severe substance use disorder or demonstrating signs of acute
substance withdrawal
6. Urine screening test positive for illicit substances
7. Active suicidal ideation (defined as an MSSI > 8) or a suicide attempt within the past
90 days
8. Any history of ECT (greater than 8 sessions) without meeting responder criteria
9. Recent (during the current depressive episode) or concurrent use of rapid acting
antidepressant agent (i.e., ketamine or a course of ECT)
10. History of significant neurologic disease, including dementia, Parkinson's or
Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple
sclerosis, or history of significant head trauma
11. Contraindication to receiving rTMS (e.g., metal in head, history of seizure, known
brain lesion)
12. Contraindication to MRI (ferromagnetic metal in their body)
13. Treatment with another investigational drug or other intervention within the study
period
14. Any other condition deemed by the PI to interfere with the study or increase risk to
the participant
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Romina Nejad, MSc
650-497-3933
I'm interested
Psoriasis Clinical Trials
Personalized Therapeutic Neuromodulation for Anhedonic Depression
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Active TBS-DLPFC
- device: Active TBS-DMPFC
- device: Sham TBS-DLPFC or DMPFC
Eligibility
Inclusion Criteria:
1. Male or Female, between the ages of 18 and 80 at the time of screening.
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Proficiency in English sufficient to complete questionnaires / follow
instructions during fMRI assessments and aiTBS interventions. Stated willingness to
comply with all study procedures, including availability for the duration of the
study, and to communicate with study personnel about adverse events and other
clinically important information.
3. Currently diagnosed with Major Depressive Disorder (MDD) or Bipolar Disorder type II
and meets criteria for a Major Depressive Episode, according to the criteria defined
in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text
Revision (DSM-5).
4. Medical records confirming a history of moderate to severe treatment-resistance as
defined by a score of 7-14 on the Maudsley Staging Method (MSM).
5. MADRS score of ≥20 at screening (Visit 1).
6. TMS naive.
7. Access to ongoing psychiatric care before and after completion of the study.
8. Must be on a stable antidepressant therapeutic regimen for 6 weeks prior to study
enrollment and agree to continue this regimen throughout the study period.
9. In good general health, as evidenced by medical history.
10. For females of reproductive potential: use of highly effective contraception for at
least 1 month prior to screening and agreement to use such a method during study
participation.
Exclusion Criteria:
1. Pregnancy
2. Primary psychiatric condition other than MDD requiring treatment except stable
co-morbid anxiety disorder
3. History of or current psychotic disorder or bipolar disorder
4. Diagnosis of Intellectual Disability or Autism Spectrum Disorder
5. Current moderate or severe substance use disorder or demonstrating signs of acute
substance withdrawal
6. Urine screening test positive for illicit substances
7. Active suicidal ideation (defined as an MSSI > 8) or a suicide attempt within the past
90 days
8. Any history of ECT (greater than 8 sessions) without meeting responder criteria
9. Recent (during the current depressive episode) or concurrent use of rapid acting
antidepressant agent (i.e., ketamine or a course of ECT)
10. History of significant neurologic disease, including dementia, Parkinson's or
Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple
sclerosis, or history of significant head trauma
11. Contraindication to receiving rTMS (e.g., metal in head, history of seizure, known
brain lesion)
12. Contraindication to MRI (ferromagnetic metal in their body)
13. Treatment with another investigational drug or other intervention within the study
period
14. Any other condition deemed by the PI to interfere with the study or increase risk to
the participant
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Romina Nejad, MSc
650-497-3933
I'm interested
Dermatology Clinical Trials
Personalized Therapeutic Neuromodulation for Anhedonic Depression
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Active TBS-DLPFC
- device: Active TBS-DMPFC
- device: Sham TBS-DLPFC or DMPFC
Eligibility
Inclusion Criteria:
1. Male or Female, between the ages of 18 and 80 at the time of screening.
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Proficiency in English sufficient to complete questionnaires / follow
instructions during fMRI assessments and aiTBS interventions. Stated willingness to
comply with all study procedures, including availability for the duration of the
study, and to communicate with study personnel about adverse events and other
clinically important information.
3. Currently diagnosed with Major Depressive Disorder (MDD) or Bipolar Disorder type II
and meets criteria for a Major Depressive Episode, according to the criteria defined
in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text
Revision (DSM-5).
4. Medical records confirming a history of moderate to severe treatment-resistance as
defined by a score of 7-14 on the Maudsley Staging Method (MSM).
5. MADRS score of ≥20 at screening (Visit 1).
6. TMS naive.
7. Access to ongoing psychiatric care before and after completion of the study.
8. Must be on a stable antidepressant therapeutic regimen for 6 weeks prior to study
enrollment and agree to continue this regimen throughout the study period.
9. In good general health, as evidenced by medical history.
10. For females of reproductive potential: use of highly effective contraception for at
least 1 month prior to screening and agreement to use such a method during study
participation.
Exclusion Criteria:
1. Pregnancy
2. Primary psychiatric condition other than MDD requiring treatment except stable
co-morbid anxiety disorder
3. History of or current psychotic disorder or bipolar disorder
4. Diagnosis of Intellectual Disability or Autism Spectrum Disorder
5. Current moderate or severe substance use disorder or demonstrating signs of acute
substance withdrawal
6. Urine screening test positive for illicit substances
7. Active suicidal ideation (defined as an MSSI > 8) or a suicide attempt within the past
90 days
8. Any history of ECT (greater than 8 sessions) without meeting responder criteria
9. Recent (during the current depressive episode) or concurrent use of rapid acting
antidepressant agent (i.e., ketamine or a course of ECT)
10. History of significant neurologic disease, including dementia, Parkinson's or
Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple
sclerosis, or history of significant head trauma
11. Contraindication to receiving rTMS (e.g., metal in head, history of seizure, known
brain lesion)
12. Contraindication to MRI (ferromagnetic metal in their body)
13. Treatment with another investigational drug or other intervention within the study
period
14. Any other condition deemed by the PI to interfere with the study or increase risk to
the participant
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Romina Nejad, MSc
650-497-3933
I'm interested
Pediatric Dermatology Clinical Trials
Personalized Therapeutic Neuromodulation for Anhedonic Depression
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Active TBS-DLPFC
- device: Active TBS-DMPFC
- device: Sham TBS-DLPFC or DMPFC
Eligibility
Inclusion Criteria:
1. Male or Female, between the ages of 18 and 80 at the time of screening.
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Proficiency in English sufficient to complete questionnaires / follow
instructions during fMRI assessments and aiTBS interventions. Stated willingness to
comply with all study procedures, including availability for the duration of the
study, and to communicate with study personnel about adverse events and other
clinically important information.
3. Currently diagnosed with Major Depressive Disorder (MDD) or Bipolar Disorder type II
and meets criteria for a Major Depressive Episode, according to the criteria defined
in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text
Revision (DSM-5).
4. Medical records confirming a history of moderate to severe treatment-resistance as
defined by a score of 7-14 on the Maudsley Staging Method (MSM).
5. MADRS score of ≥20 at screening (Visit 1).
6. TMS naive.
7. Access to ongoing psychiatric care before and after completion of the study.
8. Must be on a stable antidepressant therapeutic regimen for 6 weeks prior to study
enrollment and agree to continue this regimen throughout the study period.
9. In good general health, as evidenced by medical history.
10. For females of reproductive potential: use of highly effective contraception for at
least 1 month prior to screening and agreement to use such a method during study
participation.
Exclusion Criteria:
1. Pregnancy
2. Primary psychiatric condition other than MDD requiring treatment except stable
co-morbid anxiety disorder
3. History of or current psychotic disorder or bipolar disorder
4. Diagnosis of Intellectual Disability or Autism Spectrum Disorder
5. Current moderate or severe substance use disorder or demonstrating signs of acute
substance withdrawal
6. Urine screening test positive for illicit substances
7. Active suicidal ideation (defined as an MSSI > 8) or a suicide attempt within the past
90 days
8. Any history of ECT (greater than 8 sessions) without meeting responder criteria
9. Recent (during the current depressive episode) or concurrent use of rapid acting
antidepressant agent (i.e., ketamine or a course of ECT)
10. History of significant neurologic disease, including dementia, Parkinson's or
Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple
sclerosis, or history of significant head trauma
11. Contraindication to receiving rTMS (e.g., metal in head, history of seizure, known
brain lesion)
12. Contraindication to MRI (ferromagnetic metal in their body)
13. Treatment with another investigational drug or other intervention within the study
period
14. Any other condition deemed by the PI to interfere with the study or increase risk to
the participant
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Romina Nejad, MSc
650-497-3933
I'm interested
Personalized Therapeutic Neuromodulation for Anhedonic Depression
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Active TBS-DLPFC
- device: Active TBS-DMPFC
- device: Sham TBS-DLPFC or DMPFC
Eligibility
Inclusion Criteria:
1. Male or Female, between the ages of 18 and 80 at the time of screening.
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Proficiency in English sufficient to complete questionnaires / follow
instructions during fMRI assessments and aiTBS interventions. Stated willingness to
comply with all study procedures, including availability for the duration of the
study, and to communicate with study personnel about adverse events and other
clinically important information.
3. Currently diagnosed with Major Depressive Disorder (MDD) or Bipolar Disorder type II
and meets criteria for a Major Depressive Episode, according to the criteria defined
in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text
Revision (DSM-5).
4. Medical records confirming a history of moderate to severe treatment-resistance as
defined by a score of 7-14 on the Maudsley Staging Method (MSM).
5. MADRS score of ≥20 at screening (Visit 1).
6. TMS naive.
7. Access to ongoing psychiatric care before and after completion of the study.
8. Must be on a stable antidepressant therapeutic regimen for 6 weeks prior to study
enrollment and agree to continue this regimen throughout the study period.
9. In good general health, as evidenced by medical history.
10. For females of reproductive potential: use of highly effective contraception for at
least 1 month prior to screening and agreement to use such a method during study
participation.
Exclusion Criteria:
1. Pregnancy
2. Primary psychiatric condition other than MDD requiring treatment except stable
co-morbid anxiety disorder
3. History of or current psychotic disorder or bipolar disorder
4. Diagnosis of Intellectual Disability or Autism Spectrum Disorder
5. Current moderate or severe substance use disorder or demonstrating signs of acute
substance withdrawal
6. Urine screening test positive for illicit substances
7. Active suicidal ideation (defined as an MSSI > 8) or a suicide attempt within the past
90 days
8. Any history of ECT (greater than 8 sessions) without meeting responder criteria
9. Recent (during the current depressive episode) or concurrent use of rapid acting
antidepressant agent (i.e., ketamine or a course of ECT)
10. History of significant neurologic disease, including dementia, Parkinson's or
Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple
sclerosis, or history of significant head trauma
11. Contraindication to receiving rTMS (e.g., metal in head, history of seizure, known
brain lesion)
12. Contraindication to MRI (ferromagnetic metal in their body)
13. Treatment with another investigational drug or other intervention within the study
period
14. Any other condition deemed by the PI to interfere with the study or increase risk to
the participant
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Romina Nejad, MSc
650-497-3933
I'm interested
Personalized Therapeutic Neuromodulation for Anhedonic Depression
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Active TBS-DLPFC
- device: Active TBS-DMPFC
- device: Sham TBS-DLPFC or DMPFC
Eligibility
Inclusion Criteria:
1. Male or Female, between the ages of 18 and 80 at the time of screening.
2. Able to read, understand, and provide written, dated informed consent prior to
screening. Proficiency in English sufficient to complete questionnaires / follow
instructions during fMRI assessments and aiTBS interventions. Stated willingness to
comply with all study procedures, including availability for the duration of the
study, and to communicate with study personnel about adverse events and other
clinically important information.
3. Currently diagnosed with Major Depressive Disorder (MDD) or Bipolar Disorder type II
and meets criteria for a Major Depressive Episode, according to the criteria defined
in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text
Revision (DSM-5).
4. Medical records confirming a history of moderate to severe treatment-resistance as
defined by a score of 7-14 on the Maudsley Staging Method (MSM).
5. MADRS score of ≥20 at screening (Visit 1).
6. TMS naive.
7. Access to ongoing psychiatric care before and after completion of the study.
8. Must be on a stable antidepressant therapeutic regimen for 6 weeks prior to study
enrollment and agree to continue this regimen throughout the study period.
9. In good general health, as evidenced by medical history.
10. For females of reproductive potential: use of highly effective contraception for at
least 1 month prior to screening and agreement to use such a method during study
participation.
Exclusion Criteria:
1. Pregnancy
2. Primary psychiatric condition other than MDD requiring treatment except stable
co-morbid anxiety disorder
3. History of or current psychotic disorder or bipolar disorder
4. Diagnosis of Intellectual Disability or Autism Spectrum Disorder
5. Current moderate or severe substance use disorder or demonstrating signs of acute
substance withdrawal
6. Urine screening test positive for illicit substances
7. Active suicidal ideation (defined as an MSSI > 8) or a suicide attempt within the past
90 days
8. Any history of ECT (greater than 8 sessions) without meeting responder criteria
9. Recent (during the current depressive episode) or concurrent use of rapid acting
antidepressant agent (i.e., ketamine or a course of ECT)
10. History of significant neurologic disease, including dementia, Parkinson's or
Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple
sclerosis, or history of significant head trauma
11. Contraindication to receiving rTMS (e.g., metal in head, history of seizure, known
brain lesion)
12. Contraindication to MRI (ferromagnetic metal in their body)
13. Treatment with another investigational drug or other intervention within the study
period
14. Any other condition deemed by the PI to interfere with the study or increase risk to
the participant
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Romina Nejad, MSc
650-497-3933
I'm interested